

*Unless otherwise defined herein, capitalized terms in this announcement shall have the same meanings as those defined in the prospectus dated 16 December 2014 issued by BBI Life Sciences Corporation (the “Company”).*

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is made pursuant to section 9(2) of the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong) and is for information purposes only and does not constitute an offer or an invitation by any person to acquire, purchase or subscribe for securities of the Company.*

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement and the information contained herein do not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “U.S. Securities Act”), or the securities laws of any state of the United States, and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and any applicable state or local securities laws. There will be no public offer of securities in the United States.*

**BBI Life Sciences Corporation**  
**BBI生命科學有限公司**  
*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock code: 1035)**

**STABILIZING ACTIONS,  
END OF STABILIZATION PERIOD AND  
LAPSE OF THE OVER-ALLOTMENT OPTION**

The Company announces that the stabilization period in connection with the Global Offering ended on 18 January 2015.

Stabilizing actions were undertaken by the Stabilizing Manager during the stabilization period, further information in relation to which is set out below.

The Company further announces that the Over-Allotment Option had not been exercised by the Stabilizing Manager and the Over-Allotment Option lapsed on 18 January 2015. Accordingly, no Share was issued under the Over-Allotment Option.

## STABILIZING ACTIONS AND END OF STABILIZATION PERIOD

The Company announces that the stabilization period in connection with the Global Offering ended on 18 January 2015, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering.

The Company was informed by Haitong International Securities Company Limited, the Stabilizing Manager, that the stabilizing actions undertaken by the Stabilizing Manager, its affiliates or any person acting for it during the stabilization period were:

- (i) over-allocation of an aggregate of 19,674,000 Shares in the International Offering, representing approximately 15.0% of the Offer Shares initially offered under the Global Offering before any exercise of the Over-Allotment Option;
- (ii) the borrowing of an aggregate of 19,674,000 Shares from LJ Peace Ltd. pursuant to the stock borrowing agreement dated 19 December 2014 between the Stabilization Manager and LJ Peace Ltd. to cover the over-allocation in the International Offering (the “**Stock Borrowing Agreement**”);
- (iii) successive purchases of an aggregate of 19,833,000 Shares in the price range of HK\$1.45 to HK\$1.75 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) during the stabilization period; and
- (iv) the sell of an aggregate of 159,000 Shares in the price range of HK\$1.81 to HK\$1.82 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%) on the market during the stabilization period.

The Shares borrowed from LJ Peace Ltd. pursuant to the Stock Borrowing Agreement will be returned to LJ Peace Ltd. in accordance with the terms of the Stock Borrowing Agreement.

The last purchase made by the Stabilizing Manager on the market during the course of the stabilization period was on 16 January 2015 at the price of HK\$1.70 per Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027% and Stock Exchange trading fee of 0.005%).

## LAPSE OF THE OVER-ALLOTMENT OPTION

The Company further announces that the Over-Allotment Option had not been exercised by the Stabilizing Manager and the Over-Allotment Option lapsed on 18 January 2015. Accordingly, no Share was issued under the Over-Allotment Option.

The Company continues to comply with the public float requirements under Rule 8.08(1)(a) of the Listing Rules.

By order of the Board  
**BBI Life Sciences Corporation**  
**Wang Qisong**  
*Chairman*

Hong Kong, 19 January 2015

*As at the date of this announcement, the executive directors of the Company are Mr. WANG Qisong, Ms. WANG Luojia, and Ms. WANG Jin; the non-executive director of the Company is Mr. HU Xubo; and the independent non-executive directors of the Company are Mr. XIA Lijun, Mr. HO Kenneth Kai Chung, and Mr. LIU Jianjun.*